How to Evaluate a HealthTech Company's Tech Stack Before You Invest

HealthTech venture funding hit record deal value in 2025, with AI alone capturing 46% of all healthcare investment according to Silicon Valley Bank's proprietary analysis. Global digital health pulled in USD 29.7 billion in venture capital that year, as per Galen Growth's funding trends report. The money is flowing. But here's the uncomfortable truth: most of it is flowing blind.

Investors scrutinize revenue multiples, TAM projections, and founder pedigree. What they rarely do is crack open the hood on the technology itself. That's a problem, because in healthcare, the tech stack isn't just an implementation detail. It's the product. It's the compliance posture. It's the moat. And when it fails, it fails expensively: IBM's 2025 Cost of a Data Breach report found that healthcare breaches still cost an average of USD 7.42 million per incident, the highest figure of any industry for the fourteenth consecutive year.

This article lays out a practical framework for evaluating HealthTech technology before you commit capital. Not a checklist of buzzwords. A set of questions that separate durable platforms from expensive liabilities.

Why Tech Stack Evaluation Matters More in Healthcare Than Anywhere Else

Healthcare isn't like fintech or e-commerce, where a poorly chosen database can be swapped out over a weekend. In healthcare, your tech stack is tangled up with patient safety, regulatory exposure, and operational workflows that took years to build. The cost of getting it wrong compounds fast.

Research published in the journal Procedia Computer Science found that healthcare technology projects fail at rates up to 70% when failure is defined broadly to include delays, significant cost overruns, or inability to meet stated goals. A Stanford Health Care review presented at HIMSS23 confirmed a similar figure: roughly 70% of hospital tech pilots stall or flame out entirely. These aren't fringe projects run by underfunded startups. These are implementations at well-resourced health systems with dedicated IT departments.

The Project Management Institute estimates that underperforming organizations waste 9.9 cents of every project dollar, compared to just 4.1 cents at high-performing organizations. On a USD 50 million EHR upgrade, that gap translates to USD 2.9 million in avoidable burn per year. For investors evaluating a HealthTech company, these failure rates should trigger a simple question: does this company's architecture reduce the probability of implementation failure, or increase it?

Three factors make healthcare tech stacks uniquely high-stakes:

1. Regulatory gravity. HIPAA, GDPR, the FDA's Software-as-a-Medical-Device framework, and the proposed 2025 HIPAA Security Rule update (which eliminates the distinction between "required" and "addressable" specifications, making every control mandatory) create a compliance surface area that's both broad and punitive. OCR has settled or imposed penalties in over 152 enforcement cases totaling more than USD 144.8 million. A tech stack that wasn't designed for compliance from the ground up will hemorrhage money retrofitting it.
2. Interoperability mandates. The ONC's HTI-1 Final Rule requires support for the U.S. Core Data for Interoperability v3 via FHIR APIs. CMS mandates FHIR-based APIs for prior authorization processes by January 2026. Companies that can't demonstrate FHIR-native architecture are building on a foundation that regulators are actively dismantling.
3. Clinical integration depth. A HealthTech product that can't plug into existing EHR workflows (Epic alone covers more than 50% of all acute care multispecialty beds in the U.S.) is a product that will die in the pilot phase. Integration isn't a feature; it's a survival requirement.

The Five Pillars of HealthTech Tech Stack Due Diligence

Asking "what language is it built in?" is roughly as useful as asking a chef what brand of oven they use. You need to evaluate architecture, not ingredients. Whether a company built its platform in-house or engaged a partner specializing in custom healthcare software development, the resulting architecture should hold up under the same scrutiny. Here are the five areas that actually predict long-term viability.

Pillar 1: Compliance Architecture

Don't ask if the company is HIPAA compliant. Every company says yes. Instead, ask how compliance is embedded in the architecture.

Specific things to look for:

• Encryption at rest and in transit as a default, not an option. The proposed HIPAA Security Rule update will make this mandatory across all ePHI touchpoints. Companies that treat encryption as a configurable setting are already behind.
• Audit logging that's immutable and queryable. OCR's 2024-2025 "Risk Analysis Initiative" has made comprehensive audit trails a focal point of enforcement. If the company can't produce a detailed access log within hours of a request, that's a red flag.
• Role-based access control with granular permissions. Between 2007 and 2018, Quantros logged 18,000 EHR-related patient safety events. Many stemmed from access control failures.

The single most important question to ask: "Walk me through what happens, technically, when a breach is detected." The answer should describe automated containment, logging, notification workflows, and remediation steps. If it describes a phone call to the CTO, walk away.

Pillar 2: Interoperability and Data Architecture

The 2025 State of FHIR survey, conducted across 52 countries by HL7 International and Firely, found that 71% of respondents report active FHIR usage, up from 66% in 2024. In outpatient settings in the U.S., FHIR app adoption climbed from 49% in 2021 to 64% in 2024, according to the American Hospital Association's IT Supplement. FHIR isn't optional anymore; it's the price of admission.

When evaluating a company's data architecture, ask:

• Which FHIR version does the platform support? R4 remains dominant, but R4B and R5 are gaining traction. A company locked into a single version without a migration path is accumulating technical debt.
• How does the platform handle data normalization across different EHR systems? Epic, Cerner, and Allscripts all have quirks. The answer should involve specific mapping strategies, not hand-waving about "connectors."
• Can the platform support bidirectional data exchange, or is it read-only? Read-only integrations limit clinical utility and reduce stickiness.

A company that can't demonstrate a working FHIR API in a live demo should raise immediate concerns. Interoperability on a roadmap is different from interoperability in production.

Pillar 3: Scalability and Infrastructure

PitchBook's Q4 2025 HealthTech VC Trends report noted that deal value hit a record high in 2025, driven by larger deal sizes and AI-powered growth rounds. That means the companies getting funded are expected to scale fast. But scaling a healthcare platform is fundamentally different from scaling a consumer app. You're dealing with variable data formats, regional compliance requirements, and zero tolerance for downtime in clinical workflows.

Key questions for this pillar:

• What's the uptime SLA, and what's the actual uptime over the past 12 months? Hospitals can lose up to $900,000 per day during system downtime according to data cited by IBM. A 99.9% SLA sounds impressive until you calculate that it allows 8.7 hours of downtime per year.
• How is the infrastructure segmented for multi-tenancy? If one client's data breach can expose another client's ePHI, the architecture has a fatal flaw.
• What's the disaster recovery plan, and when was it last tested? Not documented. Tested. There's a meaningful difference.

Pillar 4: AI and Algorithm Governance

AI captured 60% of all digital health funding in 2025, reaching nearly $4 billion according to CB Insights. Six new digital health unicorns emerged in Q1 2025 alone. But AI in healthcare carries risks that don't exist in ad-tech or logistics: bias in clinical recommendations, hallucinated diagnoses, and opaque decision-making that clinicians can't audit or override.

For any HealthTech company deploying AI, investors should evaluate:

• Model transparency. Can the company explain how its model reaches a given recommendation? "It's a black box" is not acceptable when the output influences clinical decisions.
• Training data provenance. Where did the training data come from? Was it representative across demographics? The FDA is increasingly focused on algorithmic bias in SaMD submissions.
• Human-in-the-loop design. Does the system augment clinician judgment or attempt to replace it? Companies positioning AI as a replacement for clinical expertise will face regulatory and adoption headwinds. Abridge, which reached unicorn status with clinical documentation AI showing 90% utilization at leading hospitals, did so by augmenting physician workflows rather than bypassing them.
• Version control and rollback capabilities. When a model is updated, can the company revert to a previous version if performance degrades? In clinical settings, this isn't a nice-to-have; it's a safety requirement.

Pillar 5: Technical Team and Development Practices

The KPMG 2026 Healthcare & Life Sciences Investment Outlook observed that digital transformation is increasingly critical as providers seek efficiency, and that successful companies need targeted investments in digital and clinical capabilities. Translation: the technical team matters as much as the technology.

Evaluate these dimensions:

• Ratio of engineers to total headcount. A HealthTech company where engineering makes up less than 30% of the team is a company that's outsourced its core competency.
• Release cadence. How frequently does the company ship updates? Monthly or faster suggests mature CI/CD practices. Quarterly or slower may indicate brittle infrastructure or insufficient testing coverage.
• Security testing practices. Is penetration testing conducted by independent third parties? How often? Phishing was the leading initial access vector in 2025, accounting for 16% of healthcare data breaches according to IBM. A company that doesn't conduct regular pen testing is a breach waiting to happen.

Red Flags That Should Kill a Deal

Not every weakness is fixable. Some architectural decisions are so deeply embedded that they'd require a ground-up rebuild to correct. Here are the ones that should stop a deal cold:

1. No FHIR support and no credible plan to implement it. With 73% of countries that regulate health data exchange now mandating or recommending FHIR (up from 56% in 2023, per the HL7/Firely survey), a company without FHIR capability is building for a market that's disappearing.
2. Monolithic architecture with no microservices migration path. Healthcare platforms need to evolve module by module. A monolith means every update risks breaking everything, and regulatory changes in one area require regression testing across the entire codebase.
3. Single points of failure in data infrastructure. If the company can't articulate its redundancy strategy clearly and specifically, the infrastructure probably doesn't have one.
4. No independent security audit in the past 12 months. Healthcare organizations face an average of over 700 large data breaches reported annually to OCR. A company that hasn't been independently audited recently is betting that it won't be next. That's not a bet investors should co-sign.
5. Customer concentration above 40% in a single health system. This isn't strictly a tech stack issue, but it exposes whether the architecture can serve diverse deployment environments. A product that only works inside one EHR ecosystem is a services business pretending to be a platform.

Putting It All Together: A Practical Evaluation Sequence

You don't need to be a software engineer to evaluate a HealthTech tech stack effectively. You need to ask the right questions in the right order and pay attention to how confidently (and specifically) the team answers them.

Here's a sequence that works:

• Start with compliance. Ask for the most recent SOC 2 Type II report and the date of the last independent security audit. If either is missing or older than 12 months, flag it immediately.
• Move to interoperability. Request a live demo of the FHIR API. Ask to see a real data exchange with a production EHR system, not a sandbox environment.
• Evaluate scalability through customer references. Talk to two or three customers running the platform at different scales. Ask about uptime, performance under load, and the company's responsiveness to incidents.
• Probe AI governance directly. If the company uses AI, ask for documentation on model validation, bias testing, and the process for clinical review of AI outputs.
• Assess the team through their process. Ask to see the CI/CD pipeline, the incident response runbook, and the last three post-mortem reports. A team that can't produce these documents quickly doesn't have mature engineering practices.

The Bottom Line

HealthTech venture capital hit record highs in 2025, and the 2026 IPO pipeline is stacking up with companies like Omada Health and Hinge Health leading the charge. Capital is abundant. What's scarce is the discipline to evaluate whether the technology underneath these companies can actually support the valuations being placed on them.

The companies that will generate durable returns aren't necessarily the ones with the flashiest AI demos or the biggest funding rounds. They're the ones with architecture designed for a regulated, interoperable, high-stakes environment from day one. That means compliance baked into infrastructure, not bolted on. Interoperability that works in production, not on a roadmap. And engineering teams that ship consistently without breaking things.

The tech stack won't tell you everything about a HealthTech investment. But it will tell you whether the foundation is strong enough to build on, or whether you're pouring capital into a structure that's one audit, one breach, or one integration failure away from collapse.

Ask the hard questions. Demand the specifics. And don't let a compelling pitch deck substitute for architectural rigor.